GRAIL, Inc. (GRAL), a trailblazer in the healthcare sector, has attracted investor attention with its promising diagnostics and research innovations. Headquartered in Menlo Park, California, GRAIL is at the forefront of revolutionizing cancer detection with its flagship product, Galleri—a multi-cancer early detection test. As the company continues to make waves in the diagnostics industry, investors are keen to understand the potential of this $1.68 billion market cap company.

**Price and Valuation Overview**

Currently, GRAIL’s stock is priced at $43.03, experiencing a slight decrease of 0.14% today. Despite this modest dip, the stock’s 52-week range showcases a volatile journey, spanning from $21.39 to an impressive…